Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Location status: Recruiting
NCT Number: NCT07235410
Hepatocellular carcinoma (HCC) is a common liver cancer, and many patients cannot receive surgery. For these patients, transarterial chemoembolization (TACE) is an important treatment. However, patients often respond differently to TACE, and it is difficult to predict who will benefit most. This study uses deep learning to automatically analyze routine CT images taken before TACE. By measuring body composition features, such as the size and condition of different abdominal organs and tissues, we aim to better understand patients' overall health status and treatment tolerance. The goal is to develop a prediction model that can help doctors estimate survival and treatment outcomes more accurately. This may assist in making more personalized treatment decisions and improving patient care.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Wuhan, Hubei, 430022, China
Location status: Recruiting
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: After the TACE procedure until May 1, 2025
Time frame: After the TACE procedure until May 1, 2025
Contact information is provided by the study sponsor or research team.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Other
Deep Learning-Based Multidimensional Body Composition Mapping for Predicting Clinical Outcomes in Hepatocellular Carcinoma Patients Undergoing TACE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04912765
Adenocarcinoma, Carcinoma
Singapore
View Trial DetailsNCT07285044
Adenocarcinoma, Adnexal Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT07479485
Adenocarcinoma, Carcinoma
Beijing, Beijing Municipality, China
View Trial DetailsNCT07059494
Adenocarcinoma, Carcinoma
New York, United States
View Trial Details